Evidence mapPaperPMID 34209441Full record

ArticleCancers2021

A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer Risk.

Debora Macis, Valentina Aristarco, Harriet Johansson, Aliana Guerrieri-Gonzaga, Sara Raimondi, Matteo Lazzeroni, Ivana Sestak, Jack Cuzick, Andrea DeCensi, Bernardo Bonanni and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Effect of Metformin on Breast Density in Overweight/Obese Premenopausal Women.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Association of Body Composition with Pulmonary Function in Ningxia: The China Northwest Cohort.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Debora MacisDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0002-0633-2933
Valentina AristarcoDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0002-4939-6240
Harriet JohanssonDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0002-4131-2030
Aliana Guerrieri-GonzagaDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Sara RaimondiMolecular and Pharmaco-Epidemiology Unit, Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Matteo LazzeroniDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0002-2162-4002
Ivana SestakCentre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London EC1M-6BQ, UK.
Jack CuzickCentre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London EC1M-6BQ, UK.
Andrea DeCensiCentre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London EC1M-6BQ, UK.
Bernardo BonanniDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0003-3589-2128
Sara GandiniMolecular and Pharmaco-Epidemiology Unit, Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0002-1348-4548
European Institute of Oncology · ITQueen Mary University of London · GBIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

Ministero della Salute GR-2013-02358807
6 · The paper itself

Abstract

Adiponectin and leptin are adipokines secreted by the adipose tissue that are associated with several chronic diseases including cancer. We aimed to compare the immunoassay platform ELLA with an enzyme-linked immunosorbent assay (ELISA) kit and to assess whether the results of the association analyses with breast cancer risk were dependent on the assay used. We measured adiponectin and leptin with ELLA and ELISA on baseline serum samples of 116 Italian postmenopausal women enrolled in two international breast cancer prevention trials. Results were compared with Deming, Passing-Bablok regression and Bland-Altman plots. Disease-free survival was analyzed with the Cox model. There was a good correlation between the methods for adiponectin and leptin (r > 0.96). We found an increased breast cancer risk for very low adiponectin levels (HR for ELLA = 3.75; 95% CI: 1.37;10.25,

Indexed as

adiponectinbreast cancer riskELISAELLAimmunoassay platformleptin

Identifiers

PMID34209441
PMCPMC8268385
OpenAlexW3175241576

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.